<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701285</url>
  </required_header>
  <id_info>
    <org_study_id>CWP-PTV-703</org_study_id>
    <nct_id>NCT00701285</nct_id>
  </id_info>
  <brief_title>South Korean Pitavastatin Heart Failure Study</brief_title>
  <acronym>SAPHIRE</acronym>
  <official_title>A Prospective, Randomized, Two Group Comparison Study to Evaluate the Effect of Statin on Heart Function in Patients With Chronic Ischemic Heart Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <brief_summary>
    <textblock>
      We want to evaluate the utility of statins on heart function according to potency. Patients
      with chronic ischemic heart failure are administered pitavastatin 4mg or pravastatin 10mg for
      52 weeks. Then we evaluate the effect of pitavastatin and pravastatin primarily on rate of
      hospitalization for cardiovascular cause and lipid profile secondarily biomarker,
      echocardiography parameter, 6-minute walk, change of NYHA class distribution, cardiovascular
      mortality.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and number of hospitalization for cardiovascular cause; Lipid profile</measure>
    <time_frame>52week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker : BNP, hsCRP, IL-6. TNF-α</measure>
    <time_frame>52 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography : LVEF, E/A ratio, LVEDD, LVESD</measure>
    <time_frame>52 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function evaluation (NYHA class distribution, 6-minute walk test)</measure>
    <time_frame>52 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>52 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>strong statin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mild statin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pitavastatin</intervention_name>
    <description>pitavastatin 4mg once daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pravastatin</intervention_name>
    <description>pravastatin 10mg once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who accepted to enter the study by written informed consent

          2. Age ≥ 30 years

          3. LDL-cholesterol ≥ 70mg/dl

          4. Chronic heart failure of :

               -  NYHA class II ~ III

               -  Ischemic etiology

               -  Left ventricular ejection fraction &lt; 45%

               -  Optimal therapy for chronic heart failure and stable clinical condition over the
                  two weeks.

        Exclusion Criteria:

          1. Patients who participated in other studies 3 months before enrollment

          2. Statin treatment within 2 months before enrollment

          3. Unstable decompensated heart failure at enrollment

          4. Acute coronary syndrome or cerebral vascular disease within 3 months before enrollment

          5. Coronary revascularization within 3 months before enrollment or planned at enrollment

          6. Any other serious disease or condition which might effect life expectancy such as
             malignancy, life-threatening infectious disease.

          7. Serum creatinine levels &gt;= 3.0 mg/dl

          8. AST or AST levels &gt;=2.5 times of ULN

          9. CK levels &gt;=2 times of ULN

         10. Uncontrolled hypothyroidism : TSH level &gt;= 2 times of ULN

         11. Pregnant or breastfeeding women, women who want to bearing

         12. Patients who might to be unsuitable by the decision of investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Hong Baek, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>KangNam St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SEOUL St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-Ku</state>
        <zip>137-040</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>pitavastatin</keyword>
  <keyword>pravastatin</keyword>
  <keyword>statin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

